Lee et al.[57]
|
Multicenter, randomized open-label controlled trial, China
|
Supplemental oxygen: 32
Mechanical ventilation: 4
|
Influenza A
(H3N2)
(H1N1)
Influenza B
|
OR 500 OD for 5 days
|
AZT + OST: 25
OST: 25
|
At day 10:
IL-6: -83.4 % vs. - 59.5 %, P=0.017
IL-17 : -74.0 % vs. -34.3 %, P=0.011
CXCL9/MIG : -71.3 % vs. -56.0 %, P=0.031
CRP: -77.5 % vs. -48.2 %, P=0.171
|
Kakeya et al. [56]
|
Multicenter, randomized open-label clinical trial, Hong-Kong
|
Not reported
|
Influenza A
(H1N1)
|
OR 2,000 extended-release single-dose
|
AZT + OST: 56
OST: 51
|
Improvement in sore throat at day 2 (P=0.03)
Decrease in the maximum temperature on day 4 (P=0.037)
Maximum temperature on day 3-5 significantly lower (P=0.048)
|
Martin-Loeches et al.[53]
|
Multicenter, prospective observational cohort study, Spain
|
ICU admission: 100
APACHE II: 14.3
|
Influenza A
(H1N1)
|
NR
|
Macrolides: 190
CLT: 99 (52.1)
AZT: 90 (47.4)
No macrolides: 543
|
ICU mortality rate: aOR: 0.89 (95 % CI 0.53-1.49)
ICU mortality rate in mechanically ventilated: aOR: 0.77 (95 % CI
0.44-1.35)
|
Ishaqui et al. [55]
|
Multicenter, retrospective observational cohort study, Saudi
Arabia
|
Lymphocytes: 240 x109
Albumin: 4.1 g/dL
|
Influenza A
(H1N1)
|
OR/IV 500 (duration unknown)
|
AZT + OST: 102
OST: 227
|
Secondary bacterial infections: aOR: 0.285 (95 % CI, 0.1-0.81)
Respiratory support during hospitalization: aOR: 0.28 (95 % CI,
0.09-0.786)
Length of hospital stay: aOR: 0.21 (95 % CI, 0.14-0.31)
Influenza symptom severity score day 5: aOR: 0.67 (95 % CI,
0.57-0.87)
|
Arabi et al.[54]
|
Multicenter, retrospective observational cohort study, Saudi
Arabia
|
SOFA: 9
Mechanical ventilation: 61.8
|
MERS-CoV
|
NR
|
Macrolides: 136
AZT: 97 (71.3)
CLT: 28 (20.6)
ERT: 22 (16.1)
No macrolides: 213
|
90-day mortality: aOR: 0.84 (95 % CI 0.47-1.51)
RNA clearance: aHR: 0.88 (95 % CI 0.47-1.64)
|